IDL Diagnostics AB (publ) Stock Price

OM:IDLDX Community·SEK 101.4m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
1 Fair Values set on narratives written by author

Create a narrative

IDLDX Share Price Performance

SEK 0.44

0.01 (1.85%)

SEK 0.44

0.01 (1.85%)

SEK 0.44

Sun, 16 Nov 25

Share Pricen/a

IDLDX Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

Flawless balance sheet with low risk.

2 Risks

1 Reward

View Full Analysis

IDL Diagnostics AB (publ) Key Details

Last Reported Earnings

Sep 30, 2025

Next Reporting Earnings

Feb 24, 2026

: -0.086
: 40.53%
: -37.75%
: 0%

View Full Analysis

About IDLDX

Founded: 2000
Employees: 20
CEO: Anders Hultman
WebsiteView website: idldiagnostics.com

IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) in May 2025. IDL Diagnostics AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.